Молекулярная патология рака предстательной железы: диагностическая и прогностическая значимость основных маркеров

1. Gutman A.B., Gutman E.B. An Ааcid A phosphate occuring in the serum of patients with metastasizing carcinoma of the prostate gland. J Clin Invest 1938;17:473–8.

2. Ablin R.J. Prostate-specific antigen: A prognostic indicator of prostate pathophysiology. http://www.oncolink.upenn.edu/dis-ease/prostate/Ablin.html, pp. 1.10 (10/29/96 5:10 PM)

3. Ablin R.J., Soanes W.A., Bronson P., Witebsky E. Precipitating antigens of the normal human prostate. J Reprod Fertil 1970; 22: 573–4.

4. Hara M., Inorre T., Fukuyama T. Some physico-chemical characteristics of gamma-seminoprotein, an antigenic component specific for human seminal plasma. Jap. J Legal Med 1971;25:322–4.

5. Graves H.C., Sensabaugh G.F., Blake E.T. Postcoital detection of a male-specific semen protein. Application to the investigation of rape. N Engl J Med 1985; 312(6): 338–43.

6. Wang M.C., Valenzuela L.A., Murphy G.P., Chu T.M. Purification of a human prostate specific antigen. Invest Urol 1979;17: 159–63.

7. Huber P.R., Schnell Y., Hering F., Rutishauser G. Prostate specific antigen. Experimental and clinical observations.Scand J Urol Nephrol Suppl 1987;104:33–9.

8. Potosky A.L., Miller B.A., Albertsen P.C. et al. The role of detection in the rising incidence of prostate cancer. JAMA 1995;273:548–52.

9. Holmberg L., Bill-Axelson A., Helgesen F.et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002; 347:781–9.

10. Oesterling J.E. Prostate-specific antigen and diagnosing early malignancies of the prostate. J Cell Biochem Suppl 1992;16H:31–43.

11. Partin A.W., Criley S.R., Subong E.N. et al. Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis. J Urol 1996;155(4):1336–9.

12. Gilbert S.M., Cavallo C.B., Kahane H., Lowe F.C. Evidence suggesting PSA cutpoint of 2.5 ng/mL for prompting prostate biopsy: review of 36,316 biopsies. Urology 2005;65(3):549–53.

13. Saraiya M., Kottiri B.J., Leadbetter S. et al. Total and percent free prostate-specific antigen levels among U.S. men, 2001-2002. Cancer Epidemiol Biomarkers Prev 2005;14(9):2178–82.

14. Welch H.G., Schwartz L.M., Woloshin S. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst 2005;97(15):1132–7.

15. Johansson J.E., Andren O., Andersson S.O. et al. Natural history of early, localized prostate cancer. JAMA 2004;291(22):2713–9.

16. Трапезников Н.Н., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ (состояние онкологической помощи, заболеваемость и смертность). М. 2001.

17. Twyman R. M.. Principles of proteomics. BIOS Scientific Publishers, New York 2004;1:25–7.

18. Umbas R., Isaacs W.B., Bringuier P.P. et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994; 54: 3929–33.

19. Umbas R., Schalken J.A., Aalders T.W. et al. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in highgrade prostate cancer. Cancer Res 1992;52:5104–9.

20. Ross J.S., Figge H.L., Bui H.X. et al. E-cadherin expression in prostatic carcinoma biopsies: correlation with tumor grade, DNA content, pathologic stage, and clinical outcome. Mod Pathol 1994;7:835–41.

21. Jaggi M., Rao P.S., Smith D.J. et al. E-cadherin phosphorylation by protein kinase D1/protein kinase C{mu} is associated with altered cellular aggregation and motility in prostate cancer. Cancer Res 2005;65(2):483–92.

22. Rubin M.A., Mucci N.R., Figurski J. et al. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. Hum Pathol 2001;32:690–7.

23. Price J.T., Bonovich M.T., Kohn E.C. Biochemistry of cancer dissemination. Crit Rev Biochem Mol Biol 1997;32:175.

24. Chambers A.F., Matrisian L.M. Changing views of the role of matrix metallo-proteinases in metastasis. J Natl Cancer Inst 1997;89(17):1260–70.

25. Morgia G., Falsaperla M., Malaponte G. et al. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol Res 2005;33(1):44–50.

26. Semaan M., Jovenin N., Birembaut P. et al. Prognostic value of stromal immunolabelling by MMP-2, MT1-MMP and TIMP-2 in clinically localized prostate cancer. Prog Urol 2005;15(2):250–4.

27. Jiang T., Jiang H., Song X.S et al. P53 expression and its clinical significance in prostatic carcinoma. Zhonghua Nan Ke Xue 2005;11(6):448–51, 454.

28. Grignon D.J., Caplan R., Sarkar F.H. et al. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst 1997;89:158–65.

29. Kurita T., Medina R.T., Mills A.A., Cunha G.R. Role of p63 and basal cells in the prostate. Development 2004;131(20):4955–64.

30. Hameed O., Sublett J., Humphrey P.A. Immunohistochemical stains for p63 and alpha-methylacyl-CoA racemase, versus a cocktail comprising both, in the diagnosis of prostatic carcinoma: a comparison of the immunohistochemical staining of 430 foci in radical prostatectomy and needle biopsy tissues. Am J Surg Pathol 2005;29(5):579–87.

31. Kibel A.S., Faith D.A., Bova G.S. et al. Loss of heterozygosity at 12P12–13 in primary and metastatic prostate adenocarcinoma. J Urol 2000;164:192–6.

32. Kuczyk M.A., Bokemeyer C., Hartmann J. et al. Predictive value of altered p27Kip1 and p21WAF/Cip1 protein expression for the clinical prognosis of patients with localized prostate cancer. Oncol Rep 2001;8(6):1401–7.

33. Revelos K., Petraki C., Gregorakis A. et al. p27(kip1) and Ki-67 (MIB1) immunohistochemical expression in radical prostatectomy specimens of patients with clinically localized prostate cancer. In Vivo 2005;19(5):911–20.

34. Shaffer D.R., Viale A., Ishiwata R. et al. Evidence for a p27 tumor suppressive function independent of its role regulating cell proliferation in the prostate. Proc Natl Acad Sci USA 2005;102(1):210–5.

35. Maddison L.A., Sutherland B.W., Barrios R.J., Greenberg N.M. Conditional deletion of Rb causes early stage prostate cancer. Cancer Res 2004; 64(17):6018–25.

36. Morin G.B. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 1991; 59:521.

37. Kim N.W., Piatyszek M.A., Prowse K.R. et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011–5.

38. Broccoli D., Young J.W., de Lange T. Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci 1995;92: 9082–6.

39. Sommerfeld H.J., Meeker A.K., Piatyszek M.A. et al. Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res 1996;56: 218–22.

40. Botchkina G.I., Kim R.H., Botchkina I.L. et al. Noninvasive detection of prostate cancer by quantitative analysis of telomerase activity. Clin Cancer Res 2005;11(9):3243–9.

41. Kamradt J., Drosse C., Kalkbrenner S. et al. Telomerase activity and telomerase sub-unit gene expression levels are not related in prostate cancer: a real-time quantification and in situ hybridization study. Lab Invest 2003;83: 623–33.

42. Bussemakers M.J.G., van Bokhoven A., Verhaegh G.W. et al. Isaacs DD3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999;59: 5975–9.

43. de Kok J.B., Verhaegh G.W., Roelofs R.W. et al. DD3PCA3, a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002;62: 2695–8.

44. Tinzl M., Marberger M., Horvath S., Chypre C. DD3PCA3 RNA analysis in urine--a new perspective for detecting prostate cancer. Eur Urol 2004;46(2):182–6, 187.

45. Rubio J., Ramos D., Lopez-Guerrero J.A. et al. Immunohistochemical expression of ki-67 antigen, cox-2 and bax/bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens. Eur Urol 2005;48(5):745–51.

46. Rioux-Leclercq N., Leray E., Patard J.J. et al. The utility of Ki-67 expression in the differential diagnosis of prostatic intraepithelial neoplasia and ductal adenocarcinoma. Hum Pathol 2005;36(5):531–5.

47. Ojea C.A, Mosteiro C.M.J., Dominguez F.F. et al. Prognostic factors of prostate cancer: usefulness of Ki-67 expression in preoperative biopsies. Arch Esp Urol 2004;57(8):805–16.

48. Scholzen T., Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182(3):311–22.

49. Taftachi R., Ayhan A., Ekici S. et al. Proliferating-cell nuclear antigen (PCNA) as an independent prognostic marker in patients after prostatectomy: a comparison of PCNA and Ki-67. BJU Int 2005;95(4):650–4.

50. Mulligan J.M., Mai K.T., Parks W., Gerridzen R.G. Proliferating cell nuclear antigen (PCNA) and MIB 1: Markers of locally advanced and biologically aggressive prostate cancer. Can J Urol 1997;4(3):422–5.

51. Bantis A., Giannopoulos A., Gonidi M. et al. Expression of p120, Ki-67 and PCNA as proliferation biomarkers in imprint smears of prostate carcinoma and their prognostic value. Cytopathology 2004;15(1):25–31.

52. Draffin J.E., McFarlane S., Hill A. et al. Waugh D44 potentiates the adherence of metastatic prostate and breast cancer cells to one marrow endothelial cells. Cancer Res 2004;64: 5702–11.

53. Gu H., Shang P., Zhou C. Expression of CD44v6 and E-cadherin in prostate carcinoma and metastasis of prostate carcinoma. Zhonghua Nan Ke Xue 2004; 10(1): 32–4, 38.

54. Schoenfeld N., Bauer M.K., Grimm S. The metastasis suppressor gene C33/CD82/KAI1 induces apoptosis through reactive oxygen intermediates. FASEB J 2004;18(1):158–60.

55. Gao A.C., Lou W., Dong J.T. et al. Defining regulatory elements in the human KAI1 (CD 82) metastasis suppressor gene. Prostate 2003;57(4):256–60.

56. Hu W.L., Li Y.Q., He H.X. et al. KAI1/CD82 gene expression in benign prostatic hyperplasia and late-stage prostate cancer in Chinese. Asian J Androl 2000;2(3):221–4.

57. Lijovic M., Somers G., Frauman A.G. KAI1/CD82 protein expression in primary prostate cancer and in BPH associated with cancer. Cancer Detect Prev 2002; 26(1):69–77.

58. Hofer M.D., Kuefer R., Varambally S. et al. The role of metastasis-associated protein 1 in prostate cancer progression. Cancer Res 2004;64, 825–9.

59. Cloutier S.M., Chagas J.R., Mach J.-P. et al. Substrate specificity of human kallikrein 2 (hK2) as determined by phage display technology. Eur J Biochem. 2002; 269, 2747–54.

60. Diamandis E.P., Yousef G.M. Human tissue kallikreins: A family of new cancer biomarkers. Clin Chem 2002;48 (8): 1198–205.

61. Haese A., Graefen M., Steuber T. et al. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. Prostate 2001;49(2):101–9.

62. Lintula S., Stenman J., Bjartell A. et al. Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue. Prostate 2005;63(4):324–9.

63. Steuber T., Vickers A.J., Haese A. et al. Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum. Int J Cancer 2006;118(5):1234–40.

64. Wilson M.J., Haller R., Li S.Y. et al. Elevation of dipeptidylpeptidase iv activities in the prostate peripheral zone and prostatic secretions of men with prostate cancer: possible prostate cancer disease marker. J Urol 2005;174(3):1124–8.

65. Wilson M.J., Ruhland A.R., Quast B.J. et al. Dipeptidylpeptidase IV activities are elevated in prostate cancers and adjacent benign hyperplastic glands. J Androl 2000;21(2):220–6.

66. Xu J., Stolk J.A., Zhang X. et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res 2000; 60:1677–82.

67. Giovannucci E., Rimm E.B., Colditz G.A. et al. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 1993;85:1571–9.

68. Evans A.J. Alpha-methylacyl CoA racemase (P504S): overview and potential uses in diagnostic pathology as applied to prostate needle biopsies. J Clin Pathol 2003;56:892–7.

69. Nassar A., Amin M.B., Sexton D.G., Cohen C. Utility of alpha-methylacyl coenzyme A racemase (p504s antibody) as a diagnostic immunohistochemical marker for cancer. Appl Immunohistochem Mol Morphol 2005;13(3):252–5.

70. Rubin M.A., Bismar T.A., Andren O. et al. Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev 2005;14(6):1424–32.

71. Jiang Z., Li C., Fischer A. et al. Using an AMACR (P504S)/34betaE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens. Am J Clin Pathol 2005;123(2):231–6.

72. Chakravatri A., Zehr E.M., Zietman A.L. et al. Thymosin beta-15 predicts for distant failure in patients with clinically localized prostate cancer-results from a pilot study. Urology 2000;55(5):635–8.

73. Hutchinson L.M., Chang E.L., Becker C.M. et al. Use of thymosin beta15 as a urinary biomarker in human prostate cancer. Prostate 2005;64(2):116–27.